GF SEC (01776) has completed the issuance of 6 billion yuan short-term corporate bonds.
Guangfa Securities (01776) announced that according to the "Guangfa Securities Co., Ltd. 2026 Public Offering of Short-Term Corporate Bonds for Professional Investors (Fifth Tranche) Announcement", the company plans to issue short-term corporate bonds for professional investors in 2026 (hereinafter referred to as "this bond") with a planned issue size not exceeding 6 billion yuan, and an issue price of 100 yuan per bond. The issuance will be conducted through offline inquiry and allocation to professional institutional investors.
GF SEC (01776) announced that, according to the "GF SEC Limited 2026 Public Issuance of Short-Term Corporate Bonds (Fifth Tranche) for Professional Investors Announcement", GF SEC Limited plans to issue short-term corporate bonds (Fifth Tranche) for professional investors in 2026 with a total issuance size not exceeding 6 billion yuan, at a price of 100 yuan per bond, through private placement to professional institutional investors.
The issuance period for this tranche of bonds is from July 15, 2026 to July 16, 2026. Tranched One has a maturity of 287 days, with a final issuance size of 4.2 billion yuan, a final coupon rate of 1.50%, and a subscription multiple of 2.78 times. Tranched Two has a maturity of 357 days, with a final issuance size of 1.8 billion yuan, a final coupon rate of 1.51%, and a subscription multiple of 3.81 times.
Related Articles

CSPC PHARMA (01093): The Phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.

Inner Mongolia Xingye Silver & Tin Mining (000426.SZ) subsidiary plans to subscribe for 20% of the shares of the Australian listed company TAT.

Step out of the shadow of historic collapse! UnitedHealth Group Incorporated (UNH.US) significantly raises full-year guidance, blowing the horn of recovery with better-than-expected financial report.
CSPC PHARMA (01093): The Phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.

Inner Mongolia Xingye Silver & Tin Mining (000426.SZ) subsidiary plans to subscribe for 20% of the shares of the Australian listed company TAT.

Step out of the shadow of historic collapse! UnitedHealth Group Incorporated (UNH.US) significantly raises full-year guidance, blowing the horn of recovery with better-than-expected financial report.

RECOMMEND





